Evidence map›Paper›PMID 31791377›Full record

ReviewMolecular neurodegeneration2019

Organotypic brain slice cultures to model neurodegenerative proteinopathies.

C L Croft, H S Futch, B D Moore, T E Golde

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Molecular neurodegeneration, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
68citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

68 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Animal stroke models and outcome evaluation: A review.Animal models and experimental medicine · 2026
    Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Review

8 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

C L CroftDepartment of Neuroscience, College of Medicine, University of Florida, Gainesville, FL, 32610, USA.
H S FutchDepartment of Neuroscience, College of Medicine, University of Florida, Gainesville, FL, 32610, USA.
B D MooreDepartment of Neuroscience, College of Medicine, University of Florida, Gainesville, FL, 32610, USA.
T E GoldeDepartment of Neuroscience, College of Medicine, University of Florida, Gainesville, FL, 32610, USA. tgolde@ufl.edu.ORCID 0000-0003-1867-7071

Funding

Integrating the exposome and methylome to inform brain molecular changes in ADRD across established diverse cohorts.U01AG046139 · NIA · UNIVERSITY OF FLORIDA · PI ERTEKIN-TANER, NILUFER, FUNK, CORY · 2013 to 2022
$24.6M
University of Florida - Mt. Sinai Medical Center AD Research CenterP50AG047266 · NIA · UNIVERSITY OF FLORIDA · PI LOEWENSTEIN, DAVID · 2015 to 2019
$7.3M
Immune-Mediated Mechanisms Underlying CNS Abeta ClearanceR01AG018454 · NIA · UNIVERSITY OF FLORIDA · PI GOLDE, TODD E · 2000 to 2018
$5.3M
NIA NIH HHS P50 AG047266NIA NIH HHS R01 AG018454NIA NIH HHS U01 AG046139
6 · The paper itself

Abstract

Organotypic slice cultures of brain or spinal cord have been a longstanding tool in neuroscience research but their utility for understanding Alzheimer's disease (AD) and other neurodegenerative proteinopathies has only recently begun to be evaluated. Organotypic brain slice cultures (BSCs) represent a physiologically relevant three-dimensional model of the brain. BSCs support all the central nervous system (CNS) cell types and can be produced from brain areas involved in neurodegenerative disease. BSCs can be used to better understand the induction and significance of proteinopathies underlying the development and progression of AD and other neurodegenerative disorders, and in the future may serve as bridging technologies between cell culture and in vivo experiments for the development and evaluation of novel therapeutic targets and strategies. We review the initial development and general use of BSCs in neuroscience research and highlight the advantages of these cultures as an ex vivo model. Subsequently we focus on i) BSC-based modeling of AD and other neurodegenerative proteinopathies ii) use of BSCs to understand mechanisms underlying these diseases and iii) how BSCs can serve as tools to screen for suitable therapeutics prior to in vivo investigations. Finally, we will examine i) open questions regarding the use of such cultures and ii) how emerging technologies such as recombinant adeno-associated viruses (rAAV) may be combined with these models to advance translational research relevant to neurodegenerative disorders.

Indexed as

Alzheimer DiseaseAnimalsBrainDisease Models, AnimalHumansNeurodegenerative DiseasesNeuronsOrgan Culture TechniquesAlzheimer’s diseaseAmyloid-βMicrogliaNeurodegenerationOrganotypic brain slice culturesProteinopathiesRecombinant adeno-associated virusTau

Identifiers

PMID31791377
PMCPMC6889333

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.